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OBJECTIVES We conducted a pilot study to evaluate the feasibility of transendocardial delivery of
autologous bone marrow (ABM) strategy in patients with severe symptomatic chronic
myocardial ischemia not amenable to conventional revascularization.
BACKGROUND Transendocardial injection of ABM cells appears to enhance perfusion of ischemic porcine
myocardium.
METHODS Ten patients underwent transendocardial injection of freshly aspirated and filtered unfrac-
tionated ABM using left ventricular electromechanical guidance. Twelve injections of 0.2 ml
each were successfully delivered into ischemic noninfarcted myocardium pre-identified by
single-photon emission computed tomography perfusion imaging.
RESULTS Autologous bone marrow injection was successful in all patients and was associated with no
serious adverse effects; in particular, there was no arrhythmia, evidence of infection,
myocardial inflammation, or increased scar formation. Two patients were readmitted for
recurrent chest pain. At three months, Canadian Cardiovascular Society angina score
significantly improved (3.1  0.3 vs. 2.0  0.94, p  0.001), as well as stress-induced
ischemia occurring within the injected territories (2.1  0.8 vs. 1.6  0.8, p  0.001).
Treadmill exercise duration, available in nine patients, increased, but the change was not
significant (391  155 vs. 485  198, p  0.11).
CONCLUSIONS This study provides preliminary clinical data indicating feasibility of catheter-based transen-
docardial delivery of ABM to ischemic myocardium. (J Am Coll Cardiol 2003;41:1721–4)
© 2003 by the American College of Cardiology Foundation
Despite multiple clinical studies, efficacy of various angio-
genesis strategies to improve myocardial perfusion remains
unproven (1,2). Previous efforts, however, involved delivery
of a single angiogenesis factor. Given the complexity of
natural angiogenesis processes, such a strategy might pro-
vide a suboptimal stimulus to collateral development.
Therefore, we tested a cell-based strategy, based on the
hypothesis that the cells secrete, in a time- and
concentration-appropriate manner, multiple angiogenesis
factors needed for optimal collateral development.
Preclinical studies demonstrated that administration of
autologous bone marrow (ABM)-derived cells to ischemic
porcine myocardium is safe and appears to improve collat-
eral flow (3,4). The present phase I pilot study was designed
to examine the feasibility of percutaneous transendocardial
injection of unfractionated ABM in patients with advanced
coronary artery disease.
METHODS
Patient selection. Patients were eligible for the study if
they had Canadian Cardiovascular Society (CCS) angina
class III to IV despite best tolerated medical therapy, no
conventional revascularization treatment option, reversible
myocardial ischemia on single-photon emission computed
tomography imaging, and at least one major epicardial
vascular conduit with 70% and one with 70% diameter
stenosis. Exclusion criteria included abnormal hemoglobin,
platelets, or leukocyte count; conditions that may adversely
affect bone marrow (BM) (such as malignancy or human
immunodeficiency virus infection), ejection fraction (EF)
30%, and recent (1 month) myocardial infarction or
class III unstable angina. The study was approved by the
local Institutional Review Board of each of the sites and the
U.S. Food and Drug Administration. Informed consent was
obtained from all patients before enrollment.
BM. Bone marrow was aspirated from the iliac crest, mixed
with heparin (20 U per ml of BM), and filtered as previously
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described (4). Filtered BM was assessed morphologically
and tested for viability (TriPan Blue staining), absence of
clots, bone spicules, and gross bacterial contamination.
Bone marrow cell population was analyzed by fluorescence-
activated cell sorting using anti-CD34, anti-CD45, anti-
CD117, anti-CD3, anti-CD4, anti-CD8, and anti-CD41
antibodies (Becton Dickinson, Burlingame, California).
Assessment of BM-derived angiogenic growth factors.
Freshly aspirated and filtered BM cells of nine patients were
cultured for four weeks, and levels of vascular endothelial
growth factor (VEGF) and macrophage chemoattractant
protein-1 (MCP-1) in the conditioned medium were mea-
sured separately for each of the samples as previously
described (4). The effect of conditioned medium on human
umbilical endothelial cell (HUVEC) proliferation was also
measured by direct counting (4).
BM injection. Left ventricular (LV) electromechanical
mapping and injection procedures (Biosense, Johnson and
Johnson, Warren, New Jersey) have been described (5,6).
Upon completion of LV mapping, 12 injections of 0.2 ml of
BM each (total 2.4 ml) were delivered into a predefined
myocardial ischemic territory (SPECT data) approximately
1 cm apart. We avoided injecting into the LV apex or mitral
valve area (Fig. 1).
Perfusion and function. All tests were assessed at baseline
and at three-month follow-up. Myocardial perfusion was
assessed by dual isotope SPECT imaging using thallium-
201 for rest and technetium-99-sestamibi for adenosine-
stress imaging. A semiquantitative (score 0 to 4) 17-
segment model was used for analysis (7). Reversible
ischemia was defined per segment as stress-rest score 1.
Transthoracic echocardiography was used to assess global
LV function and regional wall motion (score 1 to 4) using
identical segmentation. Images were interpreted by core
laboratories blind to injection location, study sequence, and
patient clinical status. Change in perfusion was determined
by grouping and averaging stress score of all segments with
evidence of reversible ischemia at baseline lying within the
entire area of distribution of each coronary artery, whether
or not a given segment was injected. Exercise capacity was
assessed using a modified Beth-Israel/Bruce treadmill pro-
tocol.
Patient follow-up. Echocardiography was performed
within 2 h postprocedure. Serial blood samples for creatine
kinase (CK)-MB were drawn and 12-lead electrocardio-
grams were acquired over 24 h postprocedure. Follow-up
included CK-MB, complete blood count, physical exami-
nation, and event assessment. Bone marrow cultures for
bacteria and fungi were followed for one month. Changes
from baseline to three months in CCS angina class and
Abbreviations and Acronyms
ABM  autologous bone marrow
BM  bone marrow
CCS  Canadian Cardiovascular Society
CK  creatine kinase
EF  ejection fraction
HUVECs  human umbilical endothelial cells
LV  left ventricle/ventricular
MCP-1  macrophage chemoattractant protein-1
SPECT  single-photon emission computed
tomography
VEGF  vascular endothelial growth factor
Figure 1. Left ventricular electromechanical maps (left oblique, bottom
view projection) after 12 intramyocardial injections of autologous bone
marrow. Injections were delivered into an ischemic right coronary artery
territory. Local shortening (A) and unipolar voltage (B) amplitudes are
color-coded and the exact location of each of the injection sites is tagged on
the maps in real-time (black tags).
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quality of life assessed by the Seattle Angina Questionnaire
(8) were measured.
Statistical analysis. Data are presented as mean  SD.
Quantitative data were compared using paired, two-tailed
Student t test. Qualitative (categorical) data, presented as
frequencies, were compared using chi-square statistics. Re-
peated measure of variance was used to compare the
concentration of VEGF and MCP-1 in the BM-
conditioned medium collected at weeks 1, 2, 3, and 4.
One-way analysis of variance was used to compare the
effects of conditioned medium on HUVECs proliferation.
A value of p  0.05 was considered significant.
RESULTS
Patients. Baseline demographics and clinical data of the
patients are summarized in Table 1.
BM. Cell viability was 95% in all patients. The filtered
BM had no clots or bone spicules, had normal morphology,
and stained negative for bacteria. The BM aspiration and
processing time was approximated 2.5 h.
The injected BM contained 32.6  27.5106/ml nucle-
ated cells with the following cell fraction: polymorphonu-
clear cells 74.6  6.5%, lymphocytes 19.3  8.1%, mono-
cytes 3.5  1.0%, and megakaryocytes 2.6  2.3%. The
CD34 fraction was 2.6  1.6%, of which 47.9  15.1%
co-expressed CD45. Among the double positive (CD45/
CD34), 85 14% co-expressed the stem cell factor receptor
CD117 (c-kit).
Secretion of angiogenic growth factors by human BM
cells. Over a four-week period VEGF and MCP-1 levels in
the conditioned medium increased gradually from 0 to
6,472  2,448 ng/ml (p  0.001) and 2,094  293 ng/ml
(p  0.001), respectively. The BM conditioned medium
collected at four weeks increased, in a dose-related manner
(10, 50, and 100 l), proliferation of HUVECs by 25%,
50%, and 100% compared with controls (p  0.001).
Procedural data. All patients were successfully injected
with 12 injections. Left ventricular mapping and injection
were associated with induction of ventricular premature
beats, but no sustained ventricular or other arrhythmia
occurred, and no significant changes were noted in blood
pressure and heart rate.
Average mapping and BM injection procedure time was
30  13 min and 28  9 min, respectively. Overall, 45
segments were injected with an average of 4.5  1.1
injections per segment with a mean distance of 12  2 mm
between injection points.
Clinical outcomes. There were no deaths, myocardial
infarction, pericardial effusion, revascularization procedures,
or stroke. None of the patients experienced endocarditis,
myocarditis, or systemic infection, and all BM cultures were
negative for bacteria and fungi. In-hospital peak CK-MB
was within normal range in five patients and mildly elevated
(1.1 to 1.9 times upper normal) in the remaining. Troponin
I, available in eight patients, ranged between 0.16 and 0.62
ng/ml (infarction cutoff 0.8 ng/ml). All patients but one
were discharged within 24 h of the procedure. In this
patient a difficulty in advancing the mapping catheter was
noted; the procedure was completed successfully via the
other groin. Postprocedure magnetic resonance imaging
revealed confined thoracic-abdominal dissection. The pa-
tient was followed conservatively and was discharged after
three days. Three patients were readmitted to the hospital:
one for atypical and two for typical chest pains not associ-
ated with electrocardiographic changes or myocardial en-
zyme elevation.
At three months, angina symptoms improved in eight
patients and did not change in two patients, (CCS angina
class 3.1  0.3 vs. 2.0  0.94, p  0.001). Similar
improvement was noted in angina stability score (15.6 
22.9 vs. 62.5  32.7, p  0.002), angina frequency (21.3 
27.0 vs. 32.5  24.3 p  0.03), and quality of life (26.0 
17.5 vs. 46.9  23.1, p  0.01).
Myocardial perfusion and function. At baseline, a total of
62 segments had reversible ischemia: 52 within territories
subsequently injected (left anterior descending artery terri-
tory  19, left circumflex artery  23, and right coronary
artery  10) and 10 within noninjected (remote) territories.
Stress score improved in segments within the injected but
not within remote territories (Fig. 2), whereas rest score of
these segments remained unchanged (0.25  0.56 vs. 0.23
 0.47, p  0.85). There was no change in EF (47  10%
vs. 52  6%, p  0.24). The majority of segments within
the injected territories (n  91, 80%) had normal baseline
wall motion score, and none showed deterioration; among
segments with abnormal baseline score, 2 improved and 21
showed no change. Exercise duration time, in the nine
Table 1. Baseline Demographics and Clinical Data
Characteristics
Mean  SD
or n (%)
Mean age (yrs) 55  7
Male gender 7 (70)
Angina class III 9 (90)
Angina class IV 1 (10)
Systemic hypertension 6 (60)
Diabetes mellitus 5 (50)
Insulin-dependent 1 (10)
Non–insulin-dependent 4 (40)
Hyperlipidemia 9 (90)
Smoking 8 (80)
Ejection fraction (%) 47  10
Prior myocardial infarction 8 (80)
Prior bypass surgery 9 (90)
Prior PCI 10 (100)
Premature coronary artery disease 4 (40)
Nitrates 8 (80)
Beta-blockers 9 (90)
Calcium antagonists 6 (60)
Aspirin 10 (100)
Plavix 5 (50)
HMG-CoA reductase inhibitors 9 (90)
HMG-CoA  hydroxymethylglutaryl coenzyme A; PCI  percutaneous coronary
intervention.
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patients undergoing this evaluation, increased from 391 
155 to 485  198 (p  0.11).
DISCUSSION
The current study is the first to assess the feasibility and
potential safety of stand-alone transendocardial delivery of
unfractionated ABM cells in patients with advanced coro-
nary artery disease. Autologous bone marrow injection was
associated with no serious adverse effects; in particular, there
was no arrhythmia, evidence of infection, myocardial in-
flammation, or increased fibrosis. The study also suggests
potential efficacy. However, it must be emphasized that no
definitive safety- or efficacy-related conclusions can be
drawn given the small number of patients and the study
design.
We employed the ABM strategy because the BM con-
tains diverse cells capable of secreting numerous cytokines
and chemokines (3,4) as well as various progenitor and stem
cells. The activity of these cells could potentially induce
deleterious myocardial effects. We observed, however, no
evidence of myocarditis and no adverse effect on regional
myocardial perfusion or function. These results are in accord
with our porcine study (4), and with a preliminary report of
transepicardial injection of BM-derived mononuclear cells
as an adjunct to bypass grafting surgery (9).
The magnitude of clinical improvement observed in the
current study is in accord with previous trials of therapeutic
angiogenesis (1,10). However, the variable outcome of
angina symptoms among these patients, including sponta-
neous improvement, underscores the need for a large
cohort-study to control for time-dependent natural variabil-
ity and potentially important placebo effect.
The perfusion improvement we observed was in stress,
but not in rest perfusion. This is in accord with a recent
study employing transendocardial (6) delivery of VEGF, but
not with a study employing intracoronary delivery of VEGF
(11). The improvement we measured, however, may be
fortuitous and due to the relatively small number of patients
studied or to natural biologic variability in myocardial blood
flow, rather than to treatment effect.
In conclusion, transendocardial administration of freshly
aspirated ABM is potentially feasible. The results do not
prove efficacy. We believe, however, that they do warrant
larger controlled blinded studies, and should stimulate
further investigational efforts to optimize this cell-based
approach to enhancing collateral flow.
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Figure 2. Semiquantitative stress scores of segments with baseline revers-
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SPECT  single-photon emission computed tomography.
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